BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26493833)

  • 1. Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
    Lee MY; Kim HS; Lee JY; Lim SH; Kang ES; Ko YH; Kim SJ; Kim WS
    Int J Hematol; 2015 Dec; 102(6):678-88. PubMed ID: 26493833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
    Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.
    Tanaka Y; Sakai T; Tsunemine H; Ito T; Arima N
    J Clin Exp Hematop; 2024 Mar; 64(1):32-36. PubMed ID: 38417873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
    Arshad S; Fang X; Ahn KW; Kaur M; Scordo M; Sauter CS; Furqan F; Awan FT; Hamadani M
    Bone Marrow Transplant; 2023 Nov; 58(11):1203-1208. PubMed ID: 37563283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U
    Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
    Shimada K; Murase T; Matsue K; Okamoto M; Ichikawa N; Tsukamoto N; Niitsu N; Miwa H; Asaoku H; Kosugi H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamamoto K; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T;
    Cancer Sci; 2010 Jun; 101(6):1480-6. PubMed ID: 20412122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat secondary CNS involvement by aggressive lymphomas.
    Alderuccio JP; Nayak L; Cwynarski K
    Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma extramedullary relapse at the sellar and suprasellar region after autologous stem cell transplantation.
    De Jesus O
    Surg Neurol Int; 2024; 15():13. PubMed ID: 38344096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS Involvement of DLBCL Presenting with an Unusual Non-Enhancing Infiltrative Mass.
    Hsueh FS; Chen HC; Tzeng HE
    Diagnostics (Basel); 2023 Nov; 13(22):. PubMed ID: 37998560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report.
    Marangon M; Casadei B; Broccoli A; Argnani L; Cavo M; Zinzani PL
    Clin Case Rep; 2020 Jun; 8(6):933-937. PubMed ID: 32577237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based management of primary and secondary CNS lymphoma.
    Khwaja J; Nayak L; Cwynarski K
    Semin Hematol; 2023 Nov; 60(5):313-321. PubMed ID: 38135609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma with secondary central nervous system relapse: a case report and literature review.
    Tsuboi Y; Shimizu M; Kuroda A; Suyama T; Seki M; Shinagawa A
    Oxf Med Case Reports; 2023 Nov; 2023(11):omad118. PubMed ID: 38033408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
    Maciocia P; Badat M; Cheesman S; D'Sa S; Joshi R; Lambert J; Mohamedbhai S; Pule M; Linch D; Ardeshna K
    Br J Haematol; 2016 Feb; 172(4):545-53. PubMed ID: 26684148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
    Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
    Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
    Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.
    Bhatt VR; Armitage JO
    Expert Opin Biol Ther; 2016; 16(1):57-66. PubMed ID: 26515478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
    Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
    Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.
    Provencio Pulla M; Alfaro Lizaso J; de la Cruz Merino L; Gumá I Padró J; Quero Blanco C; Gómez Codina J; Llanos Muñoz M; Martinez Banaclocha N; Rodriguez Abreu D; Rueda Domínguez A
    Clin Transl Oncol; 2015 Dec; 17(12):1014-9. PubMed ID: 26586117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.